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Glomerular disease is characterised by morphological changes in podocyte cells 
accompanied by inflammation and fibrosis. Thymosin-ȕ regulates cell morphology, 
inflammation and fibrosis in several organs and administration of exogenous thymosin-ȕ
improves animal models of unilateral ureteral obstruction and diabetic nephropathy. 
However, the role of endogenous thymosin-ȕin the kidney is unknown. We demonstrate 
thymosin-ȕLVH[SUHVVHGprominently in podocytes of developing and adult mouse 
glomeruli. Global loss of thymosin-ȕGLGQRWDIIHFWKHDOWK\JORPHUXOLEXWDFFHOHUDWHGWKH
severity of immune-mediated nephrotoxic nephritis with worse renal function, peri-glomerular 
inflammation and fibrosis. Lack of thymosin-ȕin nephrotoxic nephritis led to the 
redistribution of podocytes from the glomerular tuft towards the %RZPDQ¶VFDSVXOH 
suggesting a role for thymosin-ȕLQWKHPLJUDWLRQRIWKHVHFHOOV. Thymosin-ȕknock-down 
in cultured podocytes also increased migration in a wound-healing assay; accompanied by 
F-actin rearrangement and increased RhoA activity. We propose that endogenous thymosin-
ȕLVD modifier of glomerular injury, likely having a protective role acting as a brake to slow 
disease progression. 
 





End-stage renal failure is a devastating condition, requiring life-long dialysis and 
transplantation and a risk factor for all-cause mortality and cardiovascular disease.1 Many 
cases are due to disruption of the glomerular filtration barrier, consisting of epithelial 
podocytes, endothelium, mesangium and glomerular basement membrane.2 Podocytes have 
a unique shape maintained by a complex cytoskeleton,3 with branched foot process 
extensions which abut each other at slit diaphragms. During glomerular injury, podocyte 
architecture is perturbed resulting in defective filtration and proteinuria2-4 often with 
inflammatory components characterised by leukocyte infiltration followed by 
glomerulosclerosis and tubulointerstitial fibrosis.5 
 
Thymosin-ȕ4 (Tmsbx4) is a naturally-occurring peptide. It is the major G-actin sequestering 
protein in mammalian cells6 with critical roles in maintaining the cell cytoskeleton. In animal 
models, exogenous Tmsbx4 has beneficial effects in diverse pathologies including 
myocardial infarction,7 stroke,8 dry eye9 and inflammatory lung disease;10 and there are 
clinical trials assessing Tmsbx4 treatment in wound healing and cardioprotection.11 The 
utility of Tmsbx4 in these pathologies has been attributed to modulation of several cellular 
functions including cell motility,12 differentiation,13 survival,14 angiogenesis,15 inflammation16 
and fibrosis.10  
 
Recent studies investigated exogenous Tmsbx4 as a treatment for kidney disease.17 
Tmsbx4 reduced renal tubulointerstitial fibrosis following unilateral ureteral obstruction 
(UUO) in mice, potentially through decreasing plasminogen activator inhibitor-1 (PAI-1) 
expression and dampening transforming growth factor-ȕVLJQDOOLQJ.18 In KK Cg-Ay/J mice, a 
model of type II diabetes mellitus, daily Tmsbx4 treatment for three months reduced 
albuminuria and attenuated renal pathology.19 Furthermore, N-acetyl-seryl-aspartyl-lysyl-
proline (AcSDKP), the N-terminal tetrapeptide generated by Tmsbx4 cleavage20 has 
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beneficial effects on fibrosis and inflammation in UUO, remnant kidneys, diabetic 
nephropathy and glomerulonephritis.18, 21-23 
 
Tmsbx4 transcripts are detectable by in-situ hybridisation in developing and adult glomeruli24 
with strong expression in podocytes.24, 25 Furthermore, in rat remnant kidneys, proteomic 
analysis of laser-capture dissected glomeruli demonstrated significantly increased Tmsbx4 in 
sclerotic versus normal glomeruli.26 Despite such evidence of expression and beneficial 
renal effects, the functional importance of endogenous Tmsbx4 in the kidney during health 
and disease is completely unknown.  
 
In this study, we confirmed Tmsbx4 is highly expressed in the kidney glomerulus, 
predominately in podocytes. Using global Tmsbx4 knock-out mice27 we demonstrated that 
endogenous Tmsbx4 was dispensable in healthy glomeruli. Furthermore, in an experimental 
model of glomerular damage, lack of Tmsbx4 worsened disease progression by (i) 
enhancing podocyte migration facilitating their redistribution from glomerular tuft to 
%RZPDQ¶VFDSVXOHDQG(ii) increasing peri-glomerular inflammation and interstitial fibrosis. 






Tmsb4x is expressed in mouse glomerular podocytes  
Tmsb4x mRNA levels were assessed in spleen, liver, heart and the whole kidney of healthy 
adult mice. The highest transcript levels were found in the spleen with approximately 10 
times less Tmsb4x in the kidney (Figure 1A). Using Dynabead perfusion28 we isolated 
glomeruli and found Tmsb4x levels were significantly enriched in glomeruli compared with 
the rest of the kidney (Figure 1A). In-situ hybridisation detected Tmsb4x expression in 
immature glomeruli of embryonic day (E)16.5 developing kidneys, predominately in 
podocytes (Figure 1B-C). The protein expression of Tmsb4x was also assessed by 
immunohistochemistry and we found strong localisation in glomerular podocytes at E18 
(Figure 1D). This expression pattern was maintained in one-week-old postnatal (Figure 1E) 
and eight-week-old adult kidneys (Figure 1F). Tmsb4x podocyte expression was further 
confirmed by co-localisation of Tmsb4x with nephrin (Nphs1), a slit diaphragm component29 
(Figure 1G-I) and nestin, an intermediate filament protein expressed in mature podocytes30 
(Supplementary Figure 1A-C). In contrast, Tmsbx4 did not co-localise with the pan-
endothelial marker, Cd31 (Supplementary Figure 1D-F). 
 
Lack of endogenous Tmsb4x has no effect on healthy glomeruli  
We examined mice with a global loss of Tmsb4x27 to assess the importance of endogenous 
Tmsb4x in healthy glomeruli. As Tmsb4x is mapped to the X chromosome,31 we crossed 
hemizygous null male mice (Tmsb4x-/y) with heterozygous Tmsb4x+/- adult females (Figure 
2A). We found no lethal developmental abnormalities with the offspring conforming to 
Mendelian ratios (Supplementary Table 1). Tmsb4x-/y mice had similar albumin excretion 
(Figure 2B) and blood urea nitrogen (BUN) levels (Figure 2C) as male wild-type Tmsb4x+/y 
mice at the ages of 1, 3 and 6 months. There was no difference in body weight at 1 
(Tmsb4x+/y=23.8±0.7g; Tmsb4x-/y=23.4±0.4g), 3 (Tmsb4x+/y=30.0±0.5g; Tmsb4x-
/y
=29.2±0.7g), or 6 months of age (Tmsb4x+/y=35.8±1.0g; Tmsb4x-/y=35.3±1.6g). Using semi-
quantitative analysis of light microscopy images, we found no differences in glomerular 
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morphology between six-month-old Tmsb4x+/y and Tmsb4x-/y mice (Figure 2D-F). This was 
confirmed by transmission electron microscopy with normal foot process architecture, 
laminar structure of the basement membrane and the presence of endothelial fenestrae in 
both Tmsb4x+/y and Tmsb4x-/y mice (Figure 2G-H). We demonstrated the loss of Tmsb4x 
protein in glomeruli of Tmsb4x-/y mice compared with Tmsb4x+/y (Figure 2I-J); along with 
undetectable Tmsb4x mRNA levels in whole kidneys (Figure 2K). We examined whether 
there was any compensation for the lack of Tmsb4x by other ȕ-thymosins, but found no 
changes in the renal mRNA levels of Tmsb10, Tmsb15a, Tmsb15b and Tmsb15l (Figure 2L-
O). We also assessed mRNA levels of genes involved in actin polymerisation and found no 
differences in profilin (Pfn)-1 and -2 and destrin (Dstn) between Tmsb4x-/y and Tmsb4x+/y 
mice (Supplementary Figure 2A-C). In contrast, cofilin 1 (Cfl1) mRNA levels were 
significantly increased in Tmsb4x-/y kidneys by approximately 30% compared with Tmsb4x+/y 
mice (Supplementary Figure 2D). We specifically examined Cfl1 mRNA levels in podocytes 
and found no change following knockdown of endogenous Tmsb4x by small interfering RNA 
(siRNA) (Supplementary Figure 2E). Furthermore, there was no difference in Cfl1 mRNA 
levels in primary podocytes isolated from Tmsb4x-/y and Tmsb4x+/y mice (Supplementary 
Figure 2F). Finally, the mRNA levels of genes important for podocyte function, (Nphs1, 
Nphs2, Synpo, Cd2ap and Wt1) were unchanged between Tmsb4x-/y and Tmsb4x+/y kidneys 
(Supplementary Figure 3A-E). 
 
Lack of endogenous Tmsbx4 worsens renal function and glomerular injury in NTS 
nephritis  
Our results suggest lack of Tmsbx4 does not affect the function and morphology of healthy 
glomeruli. Therefore, we investigated whether Tmsbx4 has a role in glomerular disease. We 
utilised the NTS nephritis model, which replicates some of the pathological features of 
human crescentic glomerulonephritis.32 NTS nephritis involves the injury of intrinsic 
glomerular cells, including podocytes, as well as leukocyte infiltration, glomerulosclerosis 
and tubulointerstitial fibrosis;33 processes in which Tmsbx4 has been implicated.10, 16 We 
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predicted that lack of global Tmsbx4 may exacerbate NTS nephritis severity and examined 
this in three month old Tmsb4x-/y and Tmsb4x+/y mice (Figure 3A). Albuminuria and 
albumin/creatinine ratio was significantly increased in Tmsb4x+/y mice twenty-one days after 
NTS administration compared with the levels prior to immunisation (p<0.001 in both cases, 
Figure 3B-C). Strikingly, both albuminuria and albumin/creatinine ratio was further enhanced 
by approximately 5- and 7-fold respectively when NTS was injected to Tmsb4x-/y compared 
with Tmsb4x+/y mice (p<0.01 in both cases, Figure 3B-C). Administration of NTS to Tmsb4x-
/y
 mice also significantly elevated plasma creatinine (p<0.01, Figure 3D), impaired creatinine 
clearance (p<0.01; Figure 3E) and raised BUN (p<0.05, Figure 3F) compared with 
Tmsb4x+/y mice with nephrotoxic nephritis. We found no difference in Tmsb4x levels in whole 
kidneys obtained from Tmsb4x+/y mice without disease or administered NTS 
(Supplementary Figure 4A). Furthermore, in kidney biopsies obtained from patients with 
either rapidly progressive glomerulonephritis (RPGN) or lupus nephritis (SLE), there was no 
change in glomerular or tubulointerstitial TMSB4X mRNA levels compared with living donor 
(LD) control kidneys (Supplementary Figure 4B-C). 
 
Seven days after NTS administration, we observed mild glomerular injury in Tmsb4x-/y and 
Tmsb4x+/y mice with some glomeruli containing hyaline deposits, increased mesangial matrix 
and occasional adhesion of the glomerular tuft to %RZPDQ¶VFDSVXOHSupplementary 
Figure 5A-C). After twenty-one days, there was a range of abnormalities in Tmsb4x-/y and 
Tmsb4x+/y mice injected with NTS including collapse of capillary loops, segmental or global 
glomerulosclerosis, adhesion of the tuft to %RZPDQ¶VFDSVXOHand glomerular epithelial 
hyperplasia lesions, a feature of early crescent formation in this model.34 Semi-quantitative 
histological scoring (Supplementary Figure 6A-E) by two blinded observers revealed that 
Tmsb4x+/y mice injected with NTS had significantly raised mean glomerular score compared 
with Tmsb4x+/y mice without disease (p<0.001, Figure 3G-J). Glomeruli of Tmsb4x-/y 
administered NTS had an even higher glomerular mean score which was significantly 
greater than Tmsb4x+/y mice with nephrotoxic nephritis (p<0.05). This was associated with 
8 
 
an increased proportion of sclerotic glomeruli and incidence of epithelial hyperplasia lesions 
in Tmsb4x-/y compared with Tmsb4x+/y mice administered NTS (Supplementary Figure 6F). 
 
We examined whether the difference in disease severity between Tmsb4x-/y and Tmsb4x+/y 
mice with NTS could be due to a decrease in binding of the anti-glomerular antibody but 
found no difference in the amount of sheep IgG deposited within the glomerulus 
(Supplementary Figure 7A-C). We assessed whether lack of Tmsbx4 changes the humoral 
immune response to sheep IgG. NTS injection led to significantly increased production of 
circulating murine IgG1 and IgG2a, but not IgG2b or IgG3 against sheep IgG compared with 
Tmsb4x+/y mice without disease. However there was no difference in the plasma titres of any 
of the IgG subclasses between Tmsb4x-/y and Tmsb4x+/y mice administered NTS 
(Supplementary Figure 7D-G). 
 
Changes in podocyte distribution in Tmsb4x-/y glomeruli following NTS nephritis 
Following NTS nephritis, we found that Tmsbx4 still co-localised with Nphs1 (Figure 4A-C) 
and subsequently examined the effect a lack of Tmsbx4 had on podocytes in this model. 
Firstly, we quantified WT1+ podocyte numbers,35 in and outside of the glomerular tuft (Figure 
4D-F). The number of glomerular tuft WT1+ cells was unchanged in Tmsb4x+/y mice following 
NTS injection compared with mice without disease. However, NTS administration to Tmsb4x-
/y
 mice significantly reduced the number of WT1+ glomerular tuft cells compared with 
Tmsb4x+/y mice with nephrotoxic nephritis (p<0.001; Figure 4G). This finding persisted after 
normalising the WT1+ cell number to glomerular tuft area (p<0.05; Figure 4H). In contrast, 
there was an increased number of WT1+ cells outside the glomerular tuft in both Tmsb4x+/y 
and Tmsb4x-/y mice following NTS administration, this was more prominent and significantly 
different in the Tmsb4x-/y animals (p<0.05 compared with Tmsb4x+/y without disease; Figure 
4I). The total number of podocytes in the whole glomerulus did not differ between any of the 
groups (Figure 4J), suggesting that lack of Tmsb4x leads to podocyte redistribution from the 
JORPHUXODUWXIWWRZDUGVWKH%RZPDQ¶VFDSVXOH rather than affecting podocyte cell death. To 
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support this, we assessed podocyte apoptosis using terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL)36 in combination with WT1 staining (Supplementary 
Figure 8A-C). Administration of NTS increased the number of glomerular apoptotic cells 
compared with healthy mice and this effect was significant in Tmsb4+/y mice with glomerular 
disease (p<0.05; Supplementary Figure 8D). However, the number of TUNEL+/WT1+ cells 
was not significantly different between any of the groups (Supplementary Figure 8E). 
 
Lack of Tmsb4x induces migration and modulates the cytoskeleton of podocytes in 
vitro 
We postulated that the redistribution of podocytes in nephrotoxic nephritis may be due to 
changes in cell migration driven by lack of Tmsb4x. Therefore, we transfected cultured 
differentiated mouse podocytes37 with siRNA against Tmsb4x (Figure 5A): this resulted in 
>90% knockdown in Tmsb4x levels (Figure 5B; p<0.001). Knockdown of endogenous 
Tmsb4x did not affect podocyte viability (Figure 5C) but increased the number of cells that 
migrated into the wound area in a wound-healing assay (p<0.05; Figure 5D-E). Since the 
cytoskeleton is essential for cell movement,38 we visualised podocyte actin by phalloidin 
staining and classified the filament organisation as either cytoplasmic stress fibres (Figure 
5F) or cortical actin (Figure 5G). Knockdown of endogenous Tmsb4x significantly increased 
the percentage of cells with stress actin fibre organisation (p<0.001; Figure 5H). Finally, we 
assessed the effects of Tmsb4x knockdown on the activation of RhoA and Cdc42, which 
regulate actin dynamics and cell migration.39 There was increased RhoA activity in 
podocytes transfected with Tmsb4x siRNA compared to control siRNA (p<0.05; Figure 5I) 
whereas Cdc42 activity was unaffected (Figure 5J). 
 
Macrophage accumulation and increased fibrosis in Tmsb4x-/y glomeruli following 
NTS nephritis 
Tmsb4x is expressed in macrophages18, 40 and reduces inflammation in several disease 
settings.10, 16, 18, 41 As immune cell infiltration plays a critical role in the initiation and 
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progression of crescentic glomerulonephritis.42-44 We found expression of Tmsb4x in F4/80+ 
macrophages surrounding the glomeruli and occasionally within the glomerular tuft (Figure 
6A-C) and went on to examine the effect of Tmsb4x loss on glomerular inflammation in our 
experimental model.  
 
We measured the number of Cd3+ (T cells) and F4/80+ cells in Tmsb4x-/y and Tmsb4x+/y 
glomeruli. Twenty-one days after NTS injection there was a significant increase in Cd3+ cells 
in the glomerular tuft of Tmsb4x-/y mice compared with Tmsb4x+/y without disease (p<0.05) 
but no significant difference when comparing Tmsb4x-/y andTmsb4x+/y mice with nephrotoxic 
nephritis (Figure 6D-G). There was also no difference in the number of peri-glomerular Cd3+ 
cells between experimental groups (Figure 6H). Seven days following NTS administration, 
the number of F4/80+ glomerular tuft cells was similar in all experimental groups, but were 
significantly elevated in the peri-glomerular area of both NTS-injected Tmsb4x+/y and 
Tmsb4x-/y mice compared with healthy mice (p<0.01; Supplementary Figure 9A-B). The 
accumulation of F4/80+ cells persisted in Tmsb4x-/y mice twenty-one days after NTS 
administration, with increased numbers in both the glomerular tuft and peri-glomerular area 
compared with Tmsb4x+/y mice with or without disease (p<0.01, Figure 6I-M). mRNA levels 
of the pan-macrophage marker, Cd68, were also significantly higher twenty-one days 
following NTS injection in whole kidney homogenates obtained from Tmsb4x-/y compared 
with Tmsb4x+/y mice (Supplementary Figure 10A). Cd68 is expressed by all macrophages, 
but these comprise a diverse group which includes a broad spectrum of cellular phenotypes, 
often characterised as pro-inflammatory (M1-type) and tissue repair (M2-type) macrophages. 
We quantified the mRNA levels of M1 (Mcp1, Cd86) and M2 markers (Cd206, Arg1) and 
found all of these genes were significantly upregulated in Tmsb4x-/y mice compared with 
Tmsb4x+/y following NTS (Supplementary Figure 10B-E). This suggests that there is a 
global increase in macrophages in Tmsb4x-/y kidneys following NTS rather than a shift 




Finally, the increased accumulation of macrophages in the peri-glomerular area in Tmsb4x-/y 
mice with NTS was associated with increased peri-glomerular fibrosis as shown by 
increased staining for both collagen IV (Figure 7A-C) and alpha smooth muscle actin (Į-
SMA) (Figure 7E-G) in sections from Tmsb4x-/y compared with Tmsb4x+/y mice injected with 
NTS along with increased whole kidney mRNA levels of Col4a1 (p<0.05; Figure 7D) and 





In this study we found endogenous Tmsbx4 was not required to maintain glomerular 
structure and function in healthy adult mice. However, in an experimental model of NTS 
nephritis, glomerular disease was exacerbated in mice lacking Tmsbx4 accompanied by 
changes in the distribution of podocytes within the glomerulus, increased peri-glomerular 
macrophage accumulation and enhanced fibrosis. These findings provide the first evidence 
that endogenous Tmsbx4 modifies glomerular injury, likely having a protective role acting as 
a brake to slow disease progression. 
 
We showed that Tmsbx4 is expressed in developing and adult mouse glomeruli, 
predominantly localised to podocytes. Prior studies have also found Tmsbx4 in glomerular 
podocytes,25 but others have reported complete absence of Tmsbx4 in the glomeruli of 
human fetal and adult kidneys45 and rat kidneys.26 These discrepancies may be due to 
differences in the antibodies and fixation methods used.46 Importantly, we obtained similar 
results for both Tmsb4x mRNA and protein and confirmed the specificity of antibody staining 
using tissues from Tmsb4x-/y mice as an additional negative control.  
 
Given that Tmsbx4 plays a role in actin binding,6 we initially hypothesised that lack of 
endogenous Tmsbx4 might disrupt the highly-branched architecture of glomerular podocytes 
and impair renal function.3 However, lack of Tmsbx4 did not affect glomerular morphology or 
podocyte architecture of normal healthy mice in-vivo. We found upregulation of Cfn1, which 
severs actin filaments, in whole Tmsb4x-/y kidneys. This could partly compensate for the lack 
of Tmsb4x and maintain actin dynamics,47 however, Cfn1 was not specifically altered in 
podocytes lacking Tmsb4x thus making this unlikely. 
 
A significant finding of our study was that severity of glomerular disease induced by NTS 
was greater in Tmsb4x-/y mice compared with wild-type littermates. We postulate 
endogenous Tmsb4x has a protective role in the setting of NTS, a prediction supported by a 
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study showing exogenous administration of Ac-SDKP ameliorated rat glomerulonephritis.22 
However, we found whole mouse kidney Tmsb4x mRNA levels were unchanged with NTS 
nephritis and this was mirrored when we assessed TMSB4X mRNA levels in glomerular and 
tubulointerstitial extracts from human kidneys affected by RPGN or SLE. In contrast, a 
previous study in rat remnant kidneys where nephron loss results in focal segmental 
glomerulosclerosis showed Tmsbx4 protein levels were significantly increased in sclerotic 
versus normal glomeruli.26 The discrepancy between these findings may be due to the 
different renal injury models and time-points examined. 
 
There are likely to be multiple mechanisms by which lack of endogenous Tmsb4x results in 
increased glomerular injury in our experimental model. During nephrotoxic nephritis, 
podocytes switch from a terminally-differentiated cell to a migratory cell that forms bridges 
EHWZHHQWKHJORPHUXODUWXIWDQGWKH%RZPDQ¶VFDSVXOH34 and populates glomerular 
crescents.30, 48 Lack of Tmsbx4 increased the number of glomeruli with adhesion of the tuft to 
WKH%RZPDQ¶VFDSVXOHDQGJORPHUXODUHSLWKHOLDOK\SHUSODVLDOHVLRQVDIHDWXUHRIHDUO\
crescent formation in this model.34 We also found there was a redistribution of podocytes 
from the glomerular tuft, where they contribute to filtration barrier integrity, towards the 
%RZPDQ¶VFDSVXOHOur in-vitro data demonstrates that downregulation of endogenous 
Tmsbx4 in podocytes increases migration and we predict that this may promote their 
redistribution in the nephrotoxic nephritis model. The increased podocyte migration was 
associated with increased actin stress fibres and activation of RhoA, which has been linked 
to podocyte stress fibre formation.49, 50 Moreover, podocyte-specific overexpression of RhoA 
induces proteinuria50, 51 whereas RhoA inhibition improves renal injury in mouse models of 
nephrectomy52 and nephrotoxic nephritis53, demonstrating the functional importance of this 
pathway in glomerular function. Other studies have shown RhoA activation inhibits podocyte 
migration,54 but these experiments used a constitutively active form of RhoA permanently in 
the GTP-bound state. This would result in a high degree of RhoA activity which has been 
associated with inhibition of migration.55 In contrast, Tmsbx4 knockdown led to a 2-fold 
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upregulation of RhoA activity in podocytes. It has been postulated that this lesser degree of 
RhoA activation promotes contractile stress fibre formation facilitating cell detachment in 
migrating cells39 and enhancing lamellipodia formation driving cell motility.55 It has been 
previously reported that activation of other Rho GTPases, Cdc42 and Rac1, may increase 
podocyte migration.56 However, we found that downregulation of endogenous Tmsb4x did 
not affect Cdc42 activation in podocytes. Rac1 activity was not assessed in this study and it 
would be interesting to explore its involvement in the future. 
 
Tmsb4x is also expressed in macrophages,18, 40 including in our nephrotoxic nephritis model, 
but its precise function is yet to be determined. It could be postulated that loss of 
macrophage Tmsbx4 may regulate the actin cytoskeleton which has been implicated in both 
phenotypic polarisation57 and migration.58 In our study, loss of Tmsbx4 did not alter 
macrophage polarisation or the number of activated macrophages found in the glomerular 
area in the early stages of nephrotoxic nephritis. However the number of activated 
macrophages in the peri-glomerular area at the late stage of the disease was increased in 
Tmsb4x-/y mice suggesting a deficiency in the resolution of inflammation resulting in 
persistent macrophage accumulation. Macrophage accumulation may result from an 
absence of the Tmsb4x-derivative thymosin-ȕ-sulfoxide, which has been shown to disperse 
inflammatory macrophages at the injury site in zebrafish and mouse models of heart injury.59 
We also found that peri-glomerular fibrosis was enhanced in Tmsb4x-/y mice following NTS 
administration compared with wild-type mice. This may represent a secondary effect of 
enhanced inflammation and glomerular damage. However, prior studies have shown that 
Tmsbx4 can alter both PAI-1 and TGF-ȕ18, 27 both of which are drivers of fibrosis and play 
important roles in the progression of nephrotoxic nephritis.60, 61 
 
In summary, we have provided the first evidence that lack of endogenous Tmsbx4 does not 
affect healthy glomeruli but exacerbates renal function impairment, peri-glomerular 
inflammation and fibrosis in the context of nephrotoxic nephritis. These findings suggest that 
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Experimental animals and procedures 
C57Bl/6 hemizygous null male mice (Tmsb4x-/y) were bred with heterozygous Tmsb4x+/- 
adult females to generate male wild-type (Tmsb4x+/y) and null mice.27 For the induction of 
glomerular disease Tmsb4+/y and Tmsb4x-/y mice were pre-immunised by subcutaneous 
LQMHFWLRQRIVKHHS,J*ȝJLQFRPSOHWH)UHXQG¶VDGMXYDQWIROORZHGE\LQWUDYHQRXV
administration of sheep 176ȝOILYHGD\VODWHU62 All procedures were approved by the 
UK Home Office. 
 
Renal function 
Urine was collected from mice by housing them individually in metabolic cages. Blood 
samples were collected from the lateral saphenous vein. Albumin concentrations were 
measured by enzyme-linked immunosorbent assay28, 63 (Bethyl Laboratories, Montgomery, 
TX). Urinary and plasma creatinine concentration was measured using isotope dilution 
electrospray mass spectrometry.64 &UHDWLQLQHFOHDUDQFHȝOPLQSHUJRIERG\ZHLJKWZDV
derived from the formula urinary creatinine×urine volume×1440miní1×plasma 
creatinineí1×body weight (g)í1.63 BUN was assessed using a commercially available assay 
kit, validated in mice (BioAssay Systems, Hayward, CA).65 
 
Histological Analysis and Immunohistochemistry 
.LGQH\VZHUHIL[HGLQSDUDIRUPDOGHK\GHHPEHGGHGLQSDUDIILQȝPVections cut and 
stained with periodic acid±Schiff reagent. 50 glomeruli/sample were scored by two blinded 
observers using the following system: 0=normal glomerular structure; 1=increased 
mesangial matrix deposition and hypercellularity, some loss of capillary loops; 2=increased 
matrix deposition and focal areas of sclerosis; 3=>50% of glomerulus sclerotic, very few 
capillary loops; 4=>75% of glomerulus sclerotic and presence of glomerular epithelial 




Immunohistochemistry or immunofluorescence was performed66 using antibodies against 
Tmsb4x (A9520, Immundiagnostik, Bensheim, Germany), Collagen IV (ab19808, Abcam, 
&DPEULGJH8.&GDE$EFDPĮ-SMA (M0851, Dako, Ely, UK), F4/80 
(MCA497R, AbD Serotec, Oxford, UK), Nphs1 (GP-N2, Progen, Heidelberg, Germany), 
Nestin (NB100-1604, Novus Biologicals, Littleton, CO), WT1 (AP15857PU-S, Acris 
Antibodies, Herford, Germany), Cd31 (MA3105, Thermo Fisher Scientific, Waltham, MA) and 
Sheep IgG (A11016, Thermo Fisher Scientific). CD3+ and F4/80+ cells were counted in 50 
glomeruli/sample. To assess glomerular sheep IgG deposition, mean fluorescence intensity 
was measured using ImageJ67 (30 glomeruli/sample). The number of WT1+ cells found 
within or outsiGHLQJORPHUXODUFUHVFHQWVRUOLQLQJWKH%RZPDQ¶VFDSVXOHWKHJORPHUXODUWXIW
was counted in 50 consecutive glomeruli/sample. To account for any changes in glomerular 
tuft area, the number of WT1+ cells in the glomerular tuft was normalised to the glomerular 
area (measured using ImageJ67) in 15 glomeruli/sample. Apoptosis was identified using 
TUNEL (Roche, Burgess Hill, UK). The number of TUNEL+ and WT1+/TUNEL+ cells was 
counted in 50 glomeruli/sample.  
 
Measurement of murine IgG subclasses specific for sheep IgG 
The titres of murine IgG subclasses specific for sheep IgG were measured by ELISA in 
plasma as described68 using alkaline phosphatase subclass-specific antibodies for IgG1, 
IgG2b and IgG3 (SouthernBiotech, Birmingham, AL) and IgG2a (Bethyl Laboratories). 
 
In-situ hybridisation  
In-situ hybridisation on paraffin sections was performed as described,27 using a digoxigenin-





For transmission electron microscopy, kidney cortex specimens (1mm3) were post-fixed in 
osmium tetroxide, dehydrated in acetone, and embedded in epoxy resin. Ultrathin sections 
were stained with uranyl-acetate and lead citrate and examined.  
 
Quantitative real-time PCR 
RNA was extracted from mouse whole kidney or glomerular extracts (isolated by 
Dynabeads28). 500ng was used to prepare cDNA (iScript kit, Bio-Rad, Hemel Hempstead, 
UK) and qRT-PCR performed as described28 with Hprt as a housekeeping gene. All 
measurements were performed in duplicate. Renal biopsies from patients with RPGN 
(n=12), SLE (n=12) and LD controls (n=7) were collected within the framework of the 
European Renal cDNA Bank - Kroener±Fresenius Biopsy Bank 69 after informed consent 
and local ethical approval. Unfixed tissue was transferred to RNase inhibitor and manually 
micro-dissected into glomerular and tubulointerstitial compartments. Total RNA was isolated 
and qRT-PCR performed as reported69 with 18S rRNA (Applied Biosystems) as the 
reference gene. Primer details are available on request. 
 
Cell culture 
Mouse podocytes37 were cultured as described70 and allowed to differentiate for 14 days. 
Cells were transfected with 10nM siRNA specific for Tmsb4x or with a non-targeting control 
(both from Santa Cruz Biotechnology, Dallas, TX) using the transfection reagent, 
Lipofectamine® RNAiMAX (Thermo Fisher Scientific) DFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions.  
 
Cell viability was assessed 24, 48 and 72 hours post-transfection using the 
methyltetrazolium assay. To assess migration podocytes were plated to confluence and a 
scratch created using a pipette tip. Images (four fields/condition) were taken 0, 6 and 24 
hours later and the number of cells that migrated into the wound area counted. To visualise 
F-actin filaments 48 hours post-transfection podocytes were fixed in 4% paraformaldehyde, 
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4% sucrose and stained with AlexaFluor-594 phalloidin (Thermo Fisher Scientific). The 
arrangement of actin filaments (either cytoplasmic stress fibres or cortical actin) was 
assessed in thirty cells/condition. RhoA and Cdc42 activity were quantified in podocyte 
lysates by G-LISA® Small G-protein Activation Assays (Cytoskeleton, Denver, CO). 
 
Glomeruli from Tmsb4x+/y and Tmsb4x-/y mice were isolated by Dynabeads28 and cultured in 
Matrigel-coated plates (Corning, Tewksbury, MA) in DMEM:F12 with 10% FCS, 1% ITS, 
100ȝJPOSHQLFLOOLQ7KHUPR)LVKHU6FLHQWLILF2QGD\ZKHQSRGRF\WHVKDGJURZQRXWRI
the glomeruli, they were detached using trypsin-EDTA and separated from glomeruli using 
ȝPFHOOVWUDLQHUV&RUQLQJPrimary podocytes obtained with this method were >90% pure 
as judged by cell morphology and staining using podocyte (nephrin, nestin) markers. 
 
Statistical Methods 
All samples were assessed blinded to treatment. Data is presented as means±SEM and was 
analysed using GraphPad Prism (GraphPad Software, La Jolla, CA). When differences 
between two groups were evaluated data was analysed by t-test. When three or more 
groups were assessed one-ZD\$129$ZLWK%RQIHUURQL¶VPXOWLSOHFRPSDULVRQSRVW-hoc 
tests was used. Data affected by two variables was analysed using two-way ANOVA with 











Figure 1. Tmsb4x expression in the mouse glomerulus.  
(A) Quantification of thymosin-ȕTmsb4x) mRNA levels in mouse adult spleen, liver, heart 
and kidney by qRT-PCR. Tmsb4x expression was also quantified in glomeruli-depleted 
[glom (-)] and glomeruli-enriched [glom (+)] kidney homogenates. The bars represent the 
mean of three samples ±SEM. (B-C) In situ hybridisation for Tmsb4x on E16.5 mouse kidney 
sections. Cells positive for Tmsb4x are indicated by arrows. (D-F) Immunohistochemistry for 
Tmsb4x in the mouse glomerulus at E18 (D), 1 week (E) and 8 weeks of age (F). Cells 
positive for Tmsb4x are indicated by arrows. (G-I) Representative pictures for Tmsb4x (G) 
and nephrin (Nphs1) (H) staining in the mouse adult wild-type glomerulus visualised by 
fluorescent microscopy. (I) Merged image showing Nphs1 (red) and Tmsb4x (green) 
staining; areas of co-ORFDOLVDWLRQDUHLQGLFDWHGE\DUURZV6FDOHEDU ȝPS 
 
Figure 2. Renal function and glomerular morphology in Tmsb4x+/y and Tmsb4x-/y mice.  
(A) Breeding scheme: Heterozygous female mice (Tmsb4x+/-) were bred with hemizygous 
null male mice (Tmsb4x-/y). Male wild-type (Tmsb4x+/y) and Tmsb4x-/y mice were compared in 
all subsequent experiments. (B) Twenty-four hour albumin excretion in urine of Tmsb4x+/y 
(n=14-15) and Tmsb4x-/y (n=9-10) mice collected at 1, 3, and 6 months of age. Data was log-
transformed before analysis. (C) Blood urea nitrogen (BUN) concentration in Tmsb4x+/y (n=9-
15) and Tmsb4x-/y mice (n=7-9) at 1, 3, and 6 months of age. Data was log-transformed 
before analysis. (D-E) Representative pictures of PAS staining of paraffin-embedded 
sections from Tmsb4x
+/y
 (D) and Tmsb4x-/y (E) kidneys. Scale bar = 20µm. The glomerular 
score (F) was quantified as explained in the methods (Tmsb4x+/y: n=4; Tmsb4x-/y: n=5). (G-
H) Representative images of the glomerular architecture of Tmsb4x+/y (G) and Tmsb4x-/y (H) 
kidneys assessed by transmission electron microscopy. An average of five glomeruli was 
examined per animal (Tmsb4x+/y, n=4; Tmsb4x-/y, n=3). (I-J) Representative pictures of 
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immunohistochemistry for thymosin-ȕRQSDUDIILQ-embedded sections from Tmsb4x+/y (I) 
and Tmsb4x
-/y
 (J) kidneys from 6 month old mice. Thymosin-ȕ-positive cells are indicated 
by arrows. Note: non-specific staining in tubules in Tmsb4x+/y mice and Tmsb4x-/y mice. 
Quantification of Tmsb4x (K), Tmsb10 (L), Tmsb15a (M), Tmsb15b (N) and Tmsb15l (O) 
mRNA levels in whole kidney homogenates of Tmsb4x
+/y
 (n=8) and Tmsb4x-/y (n=4) mice by 
qRT-3&5'DWDLVSUHVHQWHGDVPHDQ6(0S6FDOHEDU P 
 




 mice following the induction of 
nephrotoxic nephritis.  
(A) Outline of experimental strategy. Twenty-four hour albumin excretion in urine (B), urinary 
albumin to urinary creatinine ratio (C), plasma creatinine concentration (D), creatinine 
clearance (E) and blood urea nitrogen concentration (F) of Tmsb4x+/y and Tmsb4x-/y mice. 
6DPSOHVZHUHFROOHFWHGSULRUWRLPPXQLVDWLRQZLWK)UHXQG¶VDGMXYDQWTmsb4x+/y; control 
group) and 21 days after administration of nephrotoxic serum (Tmsb4x+/y +NTS and Tmsb4x-
/y
 +NTS); n=12 for each group. Data was log-transformed before analysis and is presented 
as mean±SEM. (G) Glomerular score was quantified as described in the methods in 
Tmsb4x
+/y
 (n=5), Tmsb4x+/y +NTS (n=9) and Tmsb4x-/y +NTS (n=6) mice. Data is presented 
as mean±SEM. Representative pictures of PAS staining in glomeruli from control mice 
(Tmsb4x+/y; H), and mice administered nephrotoxic serum (NTS) Tmsb4x+/y +NTS (I) and 
Tmsb4x
-/y
 +NTS (J) are shown. Scale bar = ȝP SSS  
 
Figure 4. Podocyte assessment in Tmsb4x+/y andTmsb4x-/y mice following the 
induction of nephrotoxic nephritis.  
(A-C) Representative picture for nephrin (Nphs1; podocytes) (A) and Tmsb4x (B) staining in 
the mouse adult wild-type glomerulus 21 days after injection with nephrotoxic serum. Cells 
positive for both Nphs1 (green) and Tmsb4x (red) are indicated by arrows in the merged 
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picture (C). (D-F) Representative pictures of glomeruli from Tmsb4x+/y (D), Tmsb4x+/y +NTS 
(E) and Tmsb4x-/y +NTS (F) mice stained for WT1. The glomerular tuft area is annotated by 
a dotted line. (G-J) Graphs showing the number of WT1-positive cells in the glomerular tuft 
(G), the number of WT1-positive cells in the glomerular tuft normalised to glomerular area 
(H), the number of WT1-positive cells in the area of the glomerulus surrounding the 
glomerular tuft (I) and the number of WT1-positive cells in the whole glomerulus (J). Cells 
were counted in 50 glomeruli per sample, except for D, where cells were counted and 
normalised to the glomerular area in 15 glomeruli per sample. Data is presented as 
mean±SEM. Tmsb4x
+/y
 (n=5), Tmsb4x+/y +NTS (n=9) and Tmsb4x-/y +NTS (n=6) mice. Scale 
EDU ȝP  
 
Figure 5: Effects of downregulating endogenous Tmsb4x expression in podocytes in 
vitro. 
(A) Podocytes grown in vitro under permissive conditions were differentiated for 14 days 
before transfecting them with control siRNA or siRNA targeting Tmsb4x. (B) Quantification of 
Tmsb4x mRNA levels in podocytes 48 hours after transfection. (C) Cell viability following 
knockdown of endogenous Tmsb4x was assessed by MTT assay. (D) Podocyte migration 
following knockdown of endogenous Tmsb4x was assessed by a wound-healing assay and 
the number of cells that migrated into the wound area was counted. (E) Representative 
pictures of podocytes transfected with control or Tmsb4x siRNA 0, 6 and 24 hours after 
wound formation. (F-G) Representative pictures showing a podocyte with cytoplasmic stress 
fibre F-actin distribution (F) or cortical F-actin distribution (G). The percentage of cells with 
predominantly cytoplasmic stress fibres or cortical actin formation was quantified 48 hours 
after transfection (H). (I-J) Quantification of active RhoA (I) and active Cdc42 (J) 48 hours 





Figure 6. Assessment of inflammation in nephrotoxic nephritis.  
(A-C) Representative picture for F4/80 (macrophages; A) and Tmsb4x staining (B). Cells 
positive for both F4/80 (green) and Tmsb4x (red) are shown in the merged picture (C) and 
are indicated by arrows. Images were taken by fluorescent PLFURVFRS\6FDOHEDU ȝP 
(D-F) Representative pictures showing Cd3 (T-cell marker) staining in the glomerular tuft 
(arrows) and in the peri-glomerular area (arrowheads) of Tmsb4x+/y controls (D) and 
Tmsb4x
+/y
 (E) and Tmsb4x-/y (F) mice 21 days following administration of nephrotoxic serum 
(NTS). The number of Cd3+ cells in the glomerular tuft (G) and in the peri-glomerular area 
(H) was counted in 50 glomeruli per sample and the average number was calculated 
(Tmsb4x+/y, n=5, Tmsb4x+/y +NTS, n=9, Tmsb4x-/y +NTS, n=6). (I-K) Representative pictures 
showing F4/80 (activated macrophage marker) staining in the glomerular tuft (arrows) and 
the peri-glomerular area (arrowheads) of Tmsb4x+/y controls (I) Tmsb4x+/y +NTS (J) and 
Tmsb4x
-/y
 +NTS (K) mice. The number of F4/80+ cells in the glomerular tuft (L) and in the 
peri-glomerular area (M) was counted in 50 glomeruli per sample and the average number 
was calculated (Tmsb4x+/y, n=5, Tmsb4x+/y +NTS, n=8, Tmsb4x-/y +NTS, n=6). Data is 
SUHVHQWHGDVPHDQ6(0SSS. Scale bar = 20µm. 
 
Figure 7. Assessment of fibrosis in nephrotoxic nephritis.  
(A-C) Representative images showing collagen IV staining in glomeruli of Tmsb4x+/y (A) 
Tmsb4x
+/y
 +NTS (B) and Tmsb4x-/y +NTS (C) mice. (N) Quantification of collagen IV 
(Col4a1) mRNA levels in whole kidney homogenates of Tmsb4x+/y (n=8), Tmsb4x+/y +NTS 
(n=9) and Tmsb4x-/y +NTS (n=6) mice. (E-G) Representative pictures showing alpha smooth 
PXVFOHDFWLQĮ-SMA) staining in glomeruli of Tmsb4x+/y (E) Tmsb4x+/y +NTS (F) and 
Tmsb4x
-/y
 +NTS (G) mice. (H) Quantification of alpha smooth muscle actin (Acta2) mRNA 
levels in whole kidney homogenates of Tmsb4x
+/y
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Supplementary Table 1 Proportions of Tmsb4x+/-, Tmsb4x-/-, Tmsb4x+/y and Tmsb4x-/y mice 
born after crossing adult male Tmsb4x-/y mice with Tmsb4x+/- adult females. 
Genotype Tmsb4x+/- Tmsb4x-/- Tmsb4x+/y Tmsb4x-/y Total ȋ2 P value 
Expected 25% 25% 25% 25%    







Supplementary Figure 1. (A-C) Representative pictures for Nestin (A) and Tmsb4x (B) 
staining in the mouse adult wild-type glomerulus visualised by fluorescent microscopy. (C) 
Merged image showing Tmsb4x (red) and Nestin (green) staining; areas of co-localisation 
are indicated by arrows. (D-F) Representative pictures for Tmsb4x (D) and Cd31 (E) staining 
in the mouse adult wild-type glomerulus visualised by fluorescent microscopy. (F) Merged 





Supplementary Figure 2. Quantification of profilin 1(Pfn1; A), profilin 2 (Pfn2; B), destrin 
(Dstn; C) and cofilin 1 (Cfl1; D) mRNA in whole kidney homogenates of Tmsb4x+/y (n=8) and 
Tmsb4x
-/y
 (n=4) mice by qRT-PCR. Quantification of cofilin 1 (Cfl1) mRNA in podocytes 48 
hours after transfection with control siRNA or siRNA targeting Tmsb4x (E, n=4) and in 










Supplementary Figure 3. Quantification of nephrin (Nphs1; A), podocin (Nphs2; B), 
synaptopodin (Synpo; C), cd2 associated protein (Cd2ap; D) and wilms tumor 1 (Wt1; E) 
mRNA in whole kidney homogenates of Tmsb4x
+/y
 (n=8) and Tmsb4x-/y (n=4) mice by qRT-













Supplementary Figure 5. Representative pictures of the histology observed 7 days after 
NTS administration showing a normal glomerulus (A), a glomerulus with hyaline deposits 
indicated by arrowheads (B) and a glomerulus with a bridge formed between the tuft and 





Supplementary Figure 6. (A-C) Representative pictures for the different scoring categories 
for glomerular injury showing (A) a normal glomerulus, score 0; (B) a glomerulus with 
increased mesangial matrix deposition and some loss of capillary loops, score 1; (C) a 
glomerulus with increased mesangial matrix deposition and focal areas of sclerosis, score 2; 
(D) a glomerulus with >50% sclerotic area and very few capillary loops, score 3 and (E) a 
sclerotic glomerulus with an epithelial hyperplastic lesion (*) and a bridge formed between 
WKHWXIWDQG%RZPDQ¶VFDSVXOHLQGLFDWHGE\DQDUURZVFRUH6FDOHEDU P(F) 
Proportions of glomeruli in the different scoring categories of glomerular injury in Tmsb4x+/y 






Supplementary Figure 7. (A-B) Representative pictures showing sheep IgG 
immunoreactivity in glomeruli of Tmsb4x
+/y
 (A) and Tmsb4x-/y (B) mice injected with NTS. (C) 
Quantification of mean fluorescence in 30 glomeruli per sample (Tmsb4x+/y +NTS, n=9; 
Tmsb4x
-/y
 +NTS, n=6). (D-G) Plasma titres of murine IgG subclasses (IgG1, D; IgG2a, E; 
IgG2b, F; IgG3, G) against Sheep IgG in control not immunised Tmsb4x+/y mice (n=5) and 
inTmsb4x+/y  (n=9) and Tmsb4x-/y  (n=6) mice 21 days after injection with nephrotoxic serum 






Supplementary Figure 8. (A-C) Representative picture showing staining for TUNEL and 
WT1 in the glomerulus. A TUNEL-positive podocyte is identified by an arrowhead (C). The 
number of TUNEL-positive cells (D) and TUNEL-positive WT-1 positive cells per glomerulus 
was counted in 50 glomeruli per sample and the average number was calculated (Tmsb4x+/y, 
n=4; Tmsb4x
+/y
 +NTS, n=9, Tmsb4x
-/y
 +NTS, n=6). Data is presented as mean±SEM. Scale 





Supplementary Figure 9. The number of F4/80+ cells in the glomerular tuft (A) and in the 
peri-glomerular area (B) 7 days following administration of nephrotoxic serum (NTS) was 
counted in 50 glomeruli per sample and the average number was calculated (Tmsb4x+/y, 
n=5, Tmsb4x
+/y








Supplementary Figure 10. Quantification of Cd68 (A), MCP-1 (B), Cd86 (C), Cd206 (D) 
and Arg1 (E) mRNA in whole kidney homogenates of Tmsb4x+/y +NTS (n=9) and Tmsb4x-/y 
+NTS (n=6) mice. 
 
